AbbVie has selected North Carolina as the site for a new $1.4 billion manufacturing campus that will integrate artificial intelligence with advanced production and laboratory technologies to support its immunology, neuroscience, and oncology medicine lines. No timeline for completion was announced. The investment reflects both the scale of AbbVie’s pipeline ambitions and a broader pharmaceutical industry trend toward AI-assisted manufacturing—applying machine learning to process optimization, quality control, and yield prediction in ways that reduce variability and regulatory risk.

Eli Lilly has announced a deal to acquire Kelonia Therapeutics, gaining access to KLN-1010, a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 trials for relapsed or refractory multiple myeloma, with data recently featured at the 2025 ASH Annual Meeting plenary session. The acquisition also brings Kelonia’s in vivo gene delivery and integration platform, which Lilly views as broadly applicable across its genetic medicine programs. The distinction between in vivo and ex vivo CAR-T is significant.